Compare AXR & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | ONCY |
|---|---|---|
| Founded | 1961 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Homebuilding | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 94.0M |
| IPO Year | 2010 | 2002 |
| Metric | AXR | ONCY |
|---|---|---|
| Price | $26.86 | $0.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $30.00 | $7.33 |
| AVG Volume (30 Days) | 10.8K | ★ 670.1K |
| Earning Date | 03-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.60 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $12,831,000.00 | N/A |
| Revenue This Year | $12.43 | N/A |
| Revenue Next Year | $4.48 | $2,505.00 |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $0.33 |
| 52 Week High | $29.00 | $1.51 |
| Indicator | AXR | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 45.33 |
| Support Level | $20.56 | $0.90 |
| Resistance Level | $28.48 | $1.08 |
| Average True Range (ATR) | 1.27 | 0.06 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 58.29 | 56.50 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.